FCGR2B: Low affinity immunoglobulin gamma Fc region receptor II-b
Receptor for the Fc region of complexed or aggregated immunoglobulins gamma.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on FCGR2B, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Obexelimab | Phase 3 | Zenas BioPharma | Antibody | InhibitorLow affinity immunoglobulin gamma Fc region receptor II-b inhibitor | 4 |
| A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) | Obexelimab | Phase 2 | Active, not recruiting | Zenas BioPharma (USA), LLC | Aug 21, 2024 |
| A Study of Obexelimab in Patients With Systemic Lupus Erythematosus | Obexelimab | Phase 2 | Active, not recruiting | Zenas BioPharma (USA), LLC | Aug 19, 2024 |
| A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre) | Obexelimab | Phase 3 | Active, not recruiting | Zenas BioPharma (USA), LLC | Mar 27, 2023 |
| A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease | Obexelimab | Phase 3 | Active, not recruiting | Zenas BioPharma (USA), LLC | Dec 22, 2022 |
- Systemic lupus erythematosus0.53
- Ulcerative colitis0.41
- Inflammatory bowel disease0.41
- Immunoglobulin G4-related sclerosing disease0.40
- Head and neck squamous cell carcinoma0.37
- Thyroid gland carcinoma0.37
- Breast ductal adenocarcinoma0.37
- Kawasaki disease0.35
- Ulcerative proctosigmoiditis0.32
- Systemic sclerosis0.31
- Rheumatoid arthritis0.30
- Melanoma0.30
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4662940, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P31994, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets